Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility
Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the next three years.
Quotient featured in Drug Development & Delivery's Outsourcing Formulation Development & Manufacturing Special Feature
Quotient's VP of Drug Development Sciences, Dr Sarah Stevens, discusses our recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities – all under one organization, in Drug Development & Delivery's Special Feature Report
Quotient's CEO featured in 2021 edition of U.S. Pharma and Biopharma Report
An interview with Quotient's CEO, Mark Egerton, was featured in the latest 2021 edition of the U.S Pharma and Biopharma Report by Global Business Reports.
Quotient featured in Drug Development & Delivery's Solubility Special Feature Report
Quotient Sciences was featured in Drug Development & Delivery's Special Feature article entitled: "Improving Bioavailability & Solubility: Each Molecule Is Unique."
Arcinova announces major investment in Alnwick site with the installation of the R1000 capsule fill machine from 3P Innovation
Arcinova, a Quotient Sciences business, announces major investment in Alnwick site with the installation of the R1000 capsule fill machine from 3P Innovation
Arcinova increases LC-MS/MS capability with addition of SCIEX 6600 Triple TOF Mass Spectrometer
Arcinova, a Quotient Sciences business, purchased the Sciex 6600 T-TOF system equipped with an Exion LC front end and Sciex BioTool software to dramatically increase its capability for not only the quantitation of large biological molecules, but also their confirmation and characterization.